Welcome to our dedicated page for Cuprina Holdings (Cayman) SEC filings (Ticker: CUPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Cuprina Holdings (Cayman)'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Cuprina Holdings (Cayman)'s regulatory disclosures and financial reporting.
Cuprina Holdings (Cayman) Limited is conducting a proposed public offering of Class A Ordinary Shares listed on Nasdaq under the symbol CUPR. The prospectus states there will be an issuance of Class A Ordinary Shares and an underwriter option to purchase additional shares.
The company reported revenue of S$49,894 (US$38,789) and a net loss of S$4,673,447 (US$3,633,248) for the year ended December 31, 2025. Immediately prior to the offering the company had 920,625 Class A and 1,760,625 Class B ordinary shares outstanding. Cuprina received FDA 510(k) clearance for its MEDIFLY products on June 12, 2026 (510(k) No. BK251252) and the Saudi FDA classified MEDIFLY as a Medical Device–Drug combination product in January 2026.
Cuprina Holdings (Cayman) Limited filed Amendment No. 1 to its 2025 annual report to revise operating and financial review, controls and procedures, and exhibits. The company develops maggot-based MEDIFLY wound-care products and cosmeceuticals, and is expanding into chronic wound solutions using bullfrog collagen and medical leeches.
Revenue was modest at S$49,894 (US$38,789) in 2025, with MEDIFLY products contributing 88.6% and Singapore accounting for most sales. High operating costs, especially professional fees tied to becoming a public company, drove a net loss of S$4,673,447 (US$3,633,248). Cash and cash equivalents reached S$3,117,682 (US$2,423,760) after IPO proceeds.
Management reported a material weakness in internal control over financial reporting related to undocumented customer contracts and concluded that disclosure controls and internal controls were ineffective as of December 31, 2025. Cuprina is trialing a new automated order and documentation process expected to be fully operational in the second half of 2026.
Cuprina Holdings (Cayman) Limited reported that its indirectly wholly owned subsidiary, Cuprina Pte. Ltd., has received U.S. FDA 510(k) clearance for MEDIFLY Maggots, a medical-grade Lucilia cuprina larvae product used in maggot debridement therapy for chronic, non-healing wounds.
The product is cleared to debride non-healing necrotic skin and soft tissue wounds such as pressure ulcers, neuropathic foot ulcers, and non-healing traumatic or post-surgical wounds. The company believes MEDIFLY Maggots is the first maggot debridement product using the Lucilia cuprina species to receive U.S. FDA 510(k) clearance.
Cuprina now holds FDA commercial rights to both species used in maggot debridement therapy, Lucilia sericata and Lucilia cuprina, which it views as a distinctive position as it builds its wound-care presence in the United States and other markets.
Cuprina Holdings (Cayman) Limited has regained compliance with Nasdaq’s listing requirements, ensuring its Class A Ordinary Shares remain listed and traded on the Nasdaq Capital Market under the symbol CUPR. The company had previously fallen below the $1.00 minimum bid price for 30 consecutive business days and did not regain compliance within the initial 180-day grace period ending May 26, 2026, triggering a Staff Delisting Determination and a planned hearing. Nasdaq Listing Qualifications staff have now advised that the company again meets the minimum bid requirement, so the July 7, 2026 hearing has been cancelled.
Cuprina Holdings (Cayman) Limited reported the results of its 2026 annual shareholder meeting. Shareholders reappointed J&S Associate PLT as auditor and re‑elected all director nominees. The meeting covered both routine governance and significant capital structure changes.
Investors approved a share consolidation that reduces issued Class A shares from 7,365,000 to 920,625 and issued Class B shares from 14,085,000 to 1,760,625, while keeping total authorised capital at US$50,000. They also backed increasing Class B voting rights from 10 to 100 votes per share and doubling authorised capital to US$100,000, split evenly between Class A and B.
Shareholders adopted a new Second Amended and Restated Memorandum and Articles of Association, approved the Cuprina 2026 Employee Incentive Plan, authorised potential future issuances that may result in a change of control or issuance of at least 20% of outstanding Class A shares, and allowed adjournment of the meeting if more proxy votes are needed.
Cuprina Holdings (Cayman) Limited files an amended report to update details for its May 14, 2026 annual general meeting. Shareholders are asked to appoint J&S Associate PLT as auditor, re-elect six directors and approve several capital and governance changes.
The board proposes a share consolidation so 7,365,000 issued Class A shares become 920,625 shares and 14,085,000 issued Class B shares become 1,760,625 shares, raising par value from US$0.001 to US$0.008 while keeping total authorised capital at US$50,000 initially. This reverse split is aimed at regaining compliance with Nasdaq’s US$1.00 minimum bid price rule before a May 26, 2026 deadline.
Proposals also include increasing Class B voting rights from 10 to 100 votes per share, doubling authorised capital to US$100,000 divided into 12,500,000 ordinary shares, adopting a Second Amended and Restated Memorandum and Articles, approving the Cuprina 2026 Employee Incentive Plan covering up to 15% of issued Class A shares, and authorising future share issuances that could exceed 20% of outstanding Class A shares or result in a change of control under Nasdaq rules. The board unanimously recommends voting in favor of all nine proposals.
Cuprina Holdings (Cayman) Limited files its Form 20-F annual report for the year ended December 31, 2025, outlining its early-stage biotech and cosmeceuticals business. The company reports net losses of S$1,119,555 in 2023, S$1,560,535 in 2024 and S$4,673,447 (US$3,633,248) in 2025.
As of December 31, 2025, Cuprina shows an accumulated deficit of S$9,234,500 (US$7,179,118) and net cash used in operating activities of S$9,133,948 (US$7,100,947). The report highlights prior net current liabilities in 2023 and 2024, dependence on IPO proceeds and shareholder financing, significant R&D needs, and extensive regulatory, competitive and operational risks around its wound care and cosmeceutical products.
Cuprina Holdings (Cayman) LTD filed a Form 3 identifying CHAN Tat Jing as an officer of the company, serving as Chief Financial Officer. The filing lists no stock or option transactions, and the transaction summary shows zero buys, sells, exercises, gifts, or other movements.
Cuprina Holdings (Cayman) LTD director and CEO QUEK David Yong Qi has filed an initial Form 3 showing indirect ownership in Class B Ordinary Shares. The filing reports 3,119,859 Class B Ordinary Shares held by Cuprina Holding Pte. Ltd. that are attributable to him through an ownership interest.
Cuprina Holding Pte. Ltd. holds a total of 14,085,000 Class B Ordinary Shares of the company, and Mr. Quek owns a 22.15% ownership interest in that entity. This Form 3 does not report new buying or selling activity; it establishes Mr. Quek’s existing indirect stake.
Cuprina Holdings (Cayman) LTD director KOH Pee Keat filed a Form 3 insider report for CUPR. The filing lists no buy, sell, acquire, or dispose transactions and shows no derivative positions in this dataset. It functions as a baseline insider ownership disclosure for this director.